Pcn356 - How Should We Validate Utility Mapping Algorithms Before Use? An Example in Non-Small Cell Lung Cancer

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.438
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Validation of Published Utility Mapping Algorithms: An Example of EORTC QLQ-C30 and EQ-5D in Non-Small Cell Lung Cancer

Health Economics Review
Health Policy
2020English

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA09.05 Can We Predict Radiosensitivity in Non-Small Cell Lung Cancer?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Health State Utility Values in Advanced Non-Small Cell Lung Cancer Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Non-Small Cell Lung Cancer

English

Are We Really Operating on Advanced Stage Non-Small Cell Lung Cancer?

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

MA21.11 Epigenomic Mapping of Cell-Free DNA in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

How to Target Small Cell Lung Cancer

Oncoscience
Cancer ResearchOncology
2015English

Staging Non-Small Cell Lung Cancer

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy